Abstract: The subject invention provides compositions and methods for inhibiting the growth and/or proliferation of cancer cells. The subject invention also provides methods for treating cancer in a subject in need of such treatment by administering a composition described herein. The subject invention can be used to inhibit cancer cell growth by exposing the cells to a composition. The subject invention further provides cancer treatments that may be used in combination with surgery, chemotherapy, and/or radiation therapy.

Abstract: Provided are a dual microparticle system to treat Multiple Sclerosis, the system comprising phagocytosable and non-phagocytosable microparticles for delivery of at least one antigen, at least one immunomodulatory agent, at least one immunosuppressive agent and at least one chemoattractant to a subject suffering from Multiple Sclerosis to generate tolerogenic dendritic cells in the subject and treat the Multiple Sclerosis.

Abstract: Disclosed herein are compositions and methods for treating obesity involving satiation gut peptide administration to the mouth of a subject for a predetermined dose and frequency. In other embodiments, materials and methods of treating certain psychological disorders are disclosed involving satiation gut peptides. In exemplary embodiments, the satiation gut peptide pertains to PYY.

Abstract: The present disclosure relates to compositions and methods for treatment of degenerative conditions of large weight-bearing joints, such as osteoarthritis, by intra-articular delivery of a codon-modified IL-1Ra encoding gene.

Abstract: A method includes in part, generating an electro-optical frequency map (EOFM) of an active layer of an integrated circuit (IC), retrieving a reference map of the IC, comparing the EOFM of the IC with the reference map to determine whether there is a match between an intensity of an identified region in the EOFM map and an intensity of a corresponding region of the reference map, and detecting one or more hardware trojans in the IC if there is no match. The reference map may be associated with a layout of an IC known not to include hardware trojans. The reference map also may be a second EOFM associated with the IC. Alternatively, the reference map may be generated by applying power to the IC, and applying a clock signal to the IC.

Abstract: Embodiments of the present disclosure provide methods, apparatus, systems, and computer program products for using an image of an integrated circuit (IC) including a plurality of cells to locate one or more target cells within the IC. Accordingly, in various embodiments, a footprint for each cell of the plurality of cells is encoded to transform the image of the IC into a two-dimensional string matrix. A string search algorithm is then applied on each encoded dopant region found in the two-dimensional string matrix using an encoded target layout cell to identify one or more candidate regions of interest within the image. Finally, a mask window is slid over each candidate region of interest while performing matching using match criteria to identify any target cells in the one or more target cells that are located within the candidate region of interest.

Abstract: The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to synthesize surface layer protein A (SlpA). Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant bacterium, for example L. lactis cells, or a therapeutically effective amount of the isolated SlpA. The recombinant bacteria cells or SlpA isolated from the recombinant bacteria can be in a pharmaceutical composition comprising a pharmaceutically acceptable carrier and/or excipient.

Abstract: Techniques include receiving a treatment plan for a subject, including a body outline, a position on a couch, and, for each gantry angle, a couch angle an isocenter and target volumes to which a radiation source is directed. A perspective transform matrix is based on projected coordinates of reference points from a digital image projector onto each different plane perpendicular to a beam from the radiation source at different distances. Two-dimensional spot positions for a gantry and couch angle are determined based on the treatment plan. A group of spot positions are determined based on a common distance from the radiation source to the body outline. Illuminated spots on a projection image are determined based on the group and the perspective transform matrix closest to the common distance. The projection image is projected from the image projector onto the subject on the couch.

Abstract: The invention relates to compounds, compositions, and methods of treating viral infection, especially SARS-CoV-2 infection.

Abstract: Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.

Abstract: Provided herein are complexes for polymerization of linear alkynes to cyclic poly(alkynes), and methods of making and using same.

Abstract: Various examples of methods and systems are provided related to functional deep neural networks (FDNNs), which can be used for high dimensional data analysis. In one example, a FDNN can be trained with a training set of omic data to produce a trained FDNN model. The likelihood of a condition can be determined based upon output indications of the FDNN corresponding to the one or more phenotypes, with the output indications based upon analysis of omic data including a multi-level omic profile from an individual by the trained FDNN. The FDNN model can include a series of basis functions as layers to capture complexity between the omic data with disease phenotypes. A treatment or prevention strategy for the individual can be identified based at least in part upon the likelihood of the condition.

Abstract: An apparatus and method are provided for performing detection of microorganisms (e.g., viruses) with high sensitivity. The apparatus and method are well suited for point-of-care (POC) testing in resource-limited regions and are capable of being operated with very little manual intervention and without the need for lab equipment. A variety of viruses can be detected with high sensitivity, including, for example, coronaviruses, Zika virus and flu viruses.

Abstract: The present invention relates to recombinant cyanobacterial cells for the production of a chemical compound of interest. In particular, the present invention relates to genetic modifications that introduce one or more heterologous phosphopantetheinyl transferases (PPTases) into a cyanobacterial cell. These cells can, optionally, further comprise heterologous carrier protein and nucleic acid constructs that provide the cyanobacterial cells with the capability of producing chemicals of interest or compounds of interest, such secondary metabolites polyketides, nonribosomal peptides and their hybrids, the three major families of bioactive natural products, of cyanobacteria and other bacterial phyla, secondary metabolites analogs, and unnatural compounds.

Abstract: The present invention provides AAV capsid proteins comprising modification of one or a combination of the surface-exposed lysine, serine, threonine and/or tyrosine residues in the VP3 region. Also provided are rAAV virions comprising the AAV capsid proteins of the present invention, as well as nucleic acid molecules and rAAV vectors encoding the AAV capsid proteins of the present invention. Advantageously, the rAAV vectors and virions of the present invention have improved efficiency in transduction of a variety of cells, tissues and organs of interest, when compared to wild-type rAAV vectors and virions.

Abstract: The disclosure provides compositions and methods for producing micro-dystrophin proteins, and the use thereof (e.g., in gene therapy). The disclosure also provides skeletal muscle-specific promoters and the use thereof (e.g., in gene therapy). The disclosure further provides catheter-based methods of delivering gene therapy vectors to skeletal muscle and/or cardiac muscle.

Abstract: The present disclosure provides the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in treating a neurological disease associated with repeat expansions and/or RAN protein accumulation, reducing the level of one or more repeat associated non-ATG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and/or biological sample. Also provided is the use of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) in inhibiting RAN protein translation in a subject and in a biological sample (e.g., cells, tissue). Also provided in the present disclosure are pharmaceutical compositions, kits, and uses of compounds of Formulae (I), (II), (III), (III-A), and (III-B) (e.g., metformin) for treating diseases associated with repeat expansions.

Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.

Abstract: The present invention provides phenazine derivatives, such as compounds of Formula (I). The compounds of the invention are expected to be antimicrobial agents and may act by a microbial warfare strategy (e.g., a reactive oxygen species (ROS)-based competition strategy). The present invention also provides compositions, kits, uses, and methods that involve the compounds of the invention, which may be useful in preventing or treating a microbial infection (e.g., a bacterial infection or mycobacterial infection) in a subject, inhibiting the growth and/or reproduction of a microorganism (e.g., a bacterium or mycobacterium), killing a microorganism (e.g., a bacterium or mycobacterium), inhibiting the formation and/or growth of a biofilm, reducing or clearing a biofilm, and/or disinfecting a surface.

Abstract: A group of quinazoline compounds has been developed that interrupt the r(CCUG)exp-MBNL1 complex and lessen pre-mRNA splicing errors due to sequestered activation and inhibition regulator MBNL1. A method of treatment of myotonic dystrophy type 2 using these quinazoline compounds has been developed.